Schott Pharma AG KGaASHTPY -42.88%64 Peter Lynch Fair Value is $4.76 as of Jul. 02, 2026, which is 275% above its 10-year median of 1.27. GuruFocus rates SHTPY with a GF Score™ of 64/100 and a GF Value™ of $7.02. The stock has 2 warning signs investors should review. Among 152 Medical Devices & Instruments companies, Schott Pharma AG KGaA ranks better than 69.08% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Schott Pharma AG KGaA's PEG is 1. Schott Pharma AG KGaA's 5-Year TTM EBITDA Growth Rate is 16.66.
Schott Pharma AG KGaA's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.29. Therefore, the Peter Lynch Fair Value for today is $4.76.
The historical rank and industry rank for Schott Pharma AG KGaA's Peter Lynch Fair Value or its related term are showing as below:
SHTPY'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.05 Med: 1.27 Max: 1.27
Current: 1.05
During the past 6 years, the highest Price to Peter Lynch Fair Value Ratio of Schott Pharma AG KGaA was 1.27. The lowest was 1.05. And the median was 1.27.
SHTPY's Price-to-Peter-Lynch-Fair-Value is ranked better than 69.08% of 152
companies
in the Medical Devices & Instruments industry
Industry Median: 1.51
vs SHTPY: 1.05
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Schott Pharma AG KGaA (OTCPK:SHTPY) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 16.66 instead of 15 in this case.
Schott Pharma AG KGaA's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
4.37
/
4.76
=
0.92
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Schott Pharma AG KGaA Peter Lynch Fair Value Related Terms
Schott Pharma AG KGaA Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for Schott Pharma AG KGaA's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Schott Pharma AG KGaA Peter Lynch Fair Value Chart
SHTPY vs ISRG, BDX, MDLN: Peter Lynch Fair Value Comparison
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA Price-to-Peter-Lynch-Fair-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's Price-to-Peter-Lynch-Fair-Value falls into.
Schott Pharma AG KGaA's EPS without NRI for the trailing twelve months (TTM) uses the latest annual data, which was $0.29.
* Note that for companies that do not have enough quarterly data to calculate the 5-Year TTM EBITDA Growth Rate, we use the annual data for the calculation.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
Schott Pharma AG KGaA (SHTPY) has a Peter Lynch Fair Value of $4.76 as of Jul. 02, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Schott Pharma AG KGaA and its competitors. This is 275% above median its historical median of 1.27. Over the past decade, Schott Pharma AG KGaA's Peter Lynch Fair Value has ranged from 1.05 to 1.27. According to the industry distribution chart, Schott Pharma AG KGaA ranks #47 out of 152 companies in the Medical Devices & Instruments industry, placing it in the top 30.9%.
Is Schott Pharma AG KGaA's Peter Lynch Fair Value too high?
Schott Pharma AG KGaA's current Peter Lynch Fair Value of $4.76 is 275% above median its 10-year median of 1.27. Over the past 10 years, this metric has ranged from a low of 1.05 to a high of 1.27. The Medical Devices & Instruments industry median Peter Lynch Fair Value is 1.51. Schott Pharma AG KGaA's value of $4.76 is 215.2% above this industry median. Based on the distribution chart, Schott Pharma AG KGaA ranks #47 out of 152 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Schott Pharma AG KGaA has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's Peter Lynch Fair Value compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #47 out of 152 companies for Peter Lynch Fair Value. This puts Schott Pharma AG KGaA in the upper half of its industry. The industry median Peter Lynch Fair Value is 1.51. Schott Pharma AG KGaA's value of $4.76 is 215.2% above this benchmark. Historically, Schott Pharma AG KGaA's own Peter Lynch Fair Value has ranged from 1.05 to 1.27 over the past decade. While the company's 10-year median is 1.27 vs. the industry median of 1.51, Schott Pharma AG KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Medical Devices & Instruments company?
The median Peter Lynch Fair Value among Medical Devices & Instruments companies is 1.51, based on 152 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Schott Pharma AG KGaA's current Peter Lynch Fair Value of $4.76 is 215.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Schott Pharma AG KGaA and its competitors. For the Medical Devices & Instruments industry, the median Peter Lynch Fair Value is 1.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current Peter Lynch Fair Value is $4.76, which is 275% above median its own 10-year median of 1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (SHTPY) has a current Peter Lynch Fair Value of $4.76. The stock's GF Value™ is $7.02, compared to a current price of $4.37 — trading 37.7% below its estimated fair value. The current Peter Lynch Fair Value is $4.76, which is 275% above median its 10-year median of 1.27 and 215.2% above the Medical Devices & Instruments industry median of 1.51. Schott Pharma AG KGaA's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Schott Pharma AG KGaA (SHTPY), the current Peter Lynch Fair Value is $4.76 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (SHTPY) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of $4.37 is trading 37.7% below its estimated GF Value™ of $7.02.
Key valuation signals for SHTPY:
Peter Lynch Fair Value: $4.76 (275% above median its 10-year median of 1.27)
GF Value™: $7.02 vs. price of $4.37 (37.7% below fair value)
Industry Position: 215.2% above the Medical Devices & Instruments median (#47 of 152)
No single metric tells the full story. See the SHTPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
64GF Score
Get the complete analysis for SHTPY
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTPY has been successfully added to your 
